Biomarin has just confirmed the initiation of the first study of BMN-111 in humans. This is a phase 1 clinical trial to verify if the CNP analogue is safe, how it is tolerated by the body, what is the path the compound follows in the body (pharmacokinetics) and the optimum dose for the treatment. The following link will take you to Biomarin site, where you can read more details.
No comments:
Post a Comment